Exploiting moderate hypoxia to benefit patients with brain disease: Molecular mechanisms and translational research in progress
Neuroprotection · 2023
DOI: 10.1002/nep3.15 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuroprotection, 2023. Verfasst von Hannelore Ehrenreich und 7 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Neuroscience, Max Planck Institute for Multidisciplinary Sciences, Göttingen, Germany. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 138 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: European Research Council.
Abstract (Originalsprache)
Hypoxia is increasingly recognized as an important physiological driving force. A specific transcriptional program, induced by a decrease in oxygen (O 2 ) availability, for example, inspiratory hypoxia at high altitude, allows cells to adapt to lower O 2 and limited energy metabolism. This transcriptional program is partly controlled by and partly independent of hypoxia‐inducible factors. Remarkably, this same transcriptional program is stimulated in the brain by extensive motor‐cognitive exercise, leading to a relative decrease in O 2 supply, compared to the acutely augmented O 2 requirement. We have coined the term “functional hypoxia” for this important demand‐responsive, relative reduction in O 2 availability. Functional hypoxia seems to be critical for enduring adaptation to higher physiological challenge that includes substantial “brain hardware upgrade,” underlying advanced performance. Hypoxia‐induced erythropoietin expression in the brain likely plays a decisive role in these processes, which can be imitated by recombinant human erythropoietin treatment. This article review presents hints of how inspiratory O 2 manipulations can potentially contribute to enhanced brain function. It thereby provides the ground for exploiting moderate inspiratory plus functional hypoxia to treat individuals with brain disease. Finally, it sketches a planned multistep pilot study in healthy volunteers and first patients, about to start, aiming at improved performance upon motor‐cognitive training under inspiratory hypoxia.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Clinical Neuroscience, Max Planck Institute for Multidisciplinary Sciences, Göttingen, Germany.
- Institute of Veterinary Physiology and Zürich Center for Integrative Human Physiology, University of Zürich, Zürich, Switzerland.
- Department of Child and Adolescent Psychiatry and Psychotherapy, University Medical Center Göttingen, Göttingen, Germany.
- Faculty of Sports Science, University of Innsbruck, Innsbruck, Austria.
- HBL Investmentpartners GmbH, München-Frankfurt, Germany.
- Departments of Neurophysiology and Neurosurgery, University of Würzburg, Würzburg, Germany.
ORCID-Profile: Hannelore Ehrenreich
Förderung
- European Research Council
Zitieren
APA
Ehrenreich, H., Gassmann, M., Poustka, L., Burtscher, M., Hammermann, P., Sirén, A. L., Nave, K. A., & Miskowiak, K. (2023). Exploiting moderate hypoxia to benefit patients with brain disease: Molecular mechanisms and translational research in progress. Neuroprotection. https://doi.org/10.1002/nep3.15
Vancouver
Ehrenreich H, Gassmann M, Poustka L, Burtscher M, Hammermann P, Sirén AL, et al. Exploiting moderate hypoxia to benefit patients with brain disease: Molecular mechanisms and translational research in progress. Neuroprotection. 2023. doi:10.1002/nep3.15
BibTeX
@article{Ehrenreich2023,
author = {Ehrenreich, Hannelore and Gassmann, Max and Poustka, Luise and Burtscher, Martin and Hammermann, Peter and Sirén, Anna-Leena and Nave, Klaus-Armin and Miskowiak, Kamilla},
title = {Exploiting moderate hypoxia to benefit patients with brain disease: Molecular mechanisms and translational research in progress},
journal = {Neuroprotection},
year = {2023},
doi = {10.1002/nep3.15}
}
EUVIMED